Levetiracetam

The effect of levetiracetam, an antiseizure therapy, on high-frequency oscillation in patients with Alzheimer’s disease as well as epilepsy may prove its viability as a biomarker of disease pathology, according to data.

For childbearing aged women with idiopathic generalized epilepsy, switching medication from valproate to levetiracetam compared with lamotrigine decreased seizure recurrence at 24 months, according to research from Neurology.

Levetiracetam was safe and may be effective in preventing acute seizures in patients with spontaneous intracerebral hemorrhage, according to clinical trial results in The Lancet Neurology.

Researchers observed differences in survival between antiseizure medications in post-stroke epilepsy, with lamotrigine and levetiracetam appearing to be reasonable first-line treatment options, according to a study in JAMA Neurology.

Patients with isocitrate dehydrogenase wild-type glioblastoma who used levetiracetam for the duration of chemoradiation may have a higher overall survival rate, according to an observational, retrospective cohort study in Neurology.

Patients with benzodiazepine-refractory convulsive status epilepticus who received a home medication vs. non-home medication did not differ in cessation of clinical seizures with improved consciousness by 60 minutes after drug initiation.